Sponsor Deadline
Posted: 4/18/2022

Proteome Characterization Centers (PCCs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science.

This FOA solicits applications for multidisciplinary Proteome Characterization Centers (PCCs). PCC awardees will be expected to work as an interactive group and use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically-characterized samples. These samples (human biospecimens and preclinical models) will be provided by the NCI.

PCCs will interact with additional CPTAC Centers that include:

  • Proteogenomic Data Analysis Centers (PGDACs, to be supported by RFA-CA-21-024; U24) that will conduct integrative analyses of data across the entire proteomes and genomes of human tumors to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level; and
  • Proteogenomic Translational Research Centers (PTRCs, to be supported under RFA-CA-21-025; U01) that will apply state-of-the-art proteomic and proteogenomic approaches to elucidate responses to cancer therapeutic agents, e.g., in order to predict which therapeutic agents are likely to be effective against a patient's tumor.


  • Letter of Intent Due Date(s): 30 days prior to application due date.

  • Application: June 30, 2021

RFA-CA-21-023 Expiration Date July 01, 2021

Eligibility Requirements

An individual designated as PD/PI on a PGDAC application in response to companion RFA-CA-21-024 (U24) cannot be designated as a PD/PI under this FOA. However, these individuals can serve as key personnel within a PCC application.

Amount Description

Application budgets for each Center may not exceed $750,000 in direct costs per year and need to reflect the actual needs of the proposed project.

Applicants may request up to 5 years of support.

Funding Type